Wade H. Aaron

652 total citations
18 papers, 404 citations indexed

About

Wade H. Aaron is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wade H. Aaron has authored 18 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wade H. Aaron's work include CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Multiple Myeloma Research and Treatments (3 papers). Wade H. Aaron is often cited by papers focused on CAR-T cell therapy research (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Multiple Myeloma Research and Treatments (3 papers). Wade H. Aaron collaborates with scholars based in United States, United Kingdom and Germany. Wade H. Aaron's co-authors include Thomas Toneff, Vivian Hook, Sukkid Yasothornsrikul, Richard J. Austin, Timothy Hoey, Derek E. Piper, Charles S. Craik, Ami S. Bhatt, Sylvia Herter and Ping Cao and has published in prestigious journals such as Blood, Biochemistry and Cancer Research.

In The Last Decade

Wade H. Aaron

17 papers receiving 386 citations

Peers

Countries citing papers authored by Wade H. Aaron

Since Specialization

Citations

This map shows the geographic impact of Wade H. Aaron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wade H. Aaron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wade H. Aaron more than expected).

Fields of papers citing papers by Wade H. Aaron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wade H. Aaron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wade H. Aaron. The network helps show where Wade H. Aaron may publish in the future.

Co-authorship network of co-authors of Wade H. Aaron

This figure shows the co-authorship network connecting the top 25 collaborators of Wade H. Aaron. A scholar is included among the top collaborators of Wade H. Aaron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wade H. Aaron. Wade H. Aaron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Abstract 5070: Anti-tumor activity of HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, is enhanced by combining with an anti-PD-L1 antibody in an immunocompetent mouse model 2023 ·Cancer Research ·(unknown), (unknown), Wade H. Aaron, (unknown), (unknown), Sen Lin, (unknown), (unknown), Holger Wesche, (unknown), Banmeet S. Anand	2
2	Abstract 2898: HPN424, a Tri-specific T-cell Activating Construct, induces T cell-mediated cytotoxicity against human metastatic castration-resistant prostate cancers (mCRPC) 2022 ·Cancer Research ·Veronica Gil, Christina Guo, George Seed, Antje Neeb, Lorenzo Buroni, Bora Gürel, Ines Figueiredo, Golzar Hemmati, Wade H. Aaron, Johann S. de Bono	0
3	Abstract 913: FLT3-targeting TriTACs are T cell engagers for treatment of acute myeloid leukemia 2021 ·Cancer Research ·Richard J. Austin, Wade H. Aaron, (unknown), (unknown), (unknown), Golzar Hemmati, Che‐Leung Law, Bryan D. Lemon, (unknown), (unknown), Morgan N. Thompson, (unknown), Holger Wesche, Kevin J. Wright, Yinghua Xiao, Stephen Yu, Timothy Z. Yu	1
4	The Effects of BCMA Expression, Soluble BCMA, and Combination Therapeutics on the Anti-Tumor Activity of HPN217, a BCMA-Targeting Tri-Specific T Cell Engager Against Multiple Myeloma 2021 ·Blood ·Patrick P. Ng, Wade H. Aaron, (unknown), Golzar Hemmati, Che‐Leung Law, Abdel Kareem Azab, (unknown)	1
5	Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors 2020 ·Clinical Cancer Research ·(unknown), Richard J. Austin, Bryan D. Lemon, Wade H. Aaron, (unknown), (unknown), Susan Dana Jones, (unknown), (unknown), Kenneth G. Sexton, (unknown), Timothy Z. Yu, Patrick A. Baeuerle, Che‐Leung Law, Holger Wesche	35
6	Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of small cell lung cancer 2019 ·Molecular Cancer Therapeutics ·Wade H. Aaron, Richard J. Austin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Golzar Hemmati, (unknown), Che‐Leung Law, Bryan D. Lemon, (unknown), (unknown), (unknown), (unknown), Holger Wesche, Stephen Yu, Timothy Z. Yu	11
7	Abstract 1773: HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer 2018 ·Cancer Research ·Bryan D. Lemon, Wade H. Aaron, Richard J. Austin, Patrick A. Baeuerle, (unknown), (unknown), Susan Dana Jones, (unknown), Che‐Leung Law, (unknown), Kenneth G. Sexton, (unknown), Holger Wesche, Timothy Z. Yu	6
8	Abstract 1781: HPN536, a T cell-engaging, mesothelin/CD3-specific TriTAC for the treatment of solid tumors 2018 ·Cancer Research ·Richard J. Austin, Wade H. Aaron, Patrick A. Baeuerle, (unknown), (unknown), Susan Dana Jones, Che‐Leung Law, (unknown), Bryan D. Lemon, (unknown), Kenneth G. Sexton, (unknown), Holger Wesche, Timothy Z. Yu	7
9	Abstract 3814: TriTACs are novel T cell-engaging therapeutic proteins optimized for the treatment of solid tumors and for long serum half-life 2018 ·Cancer Research ·Holger Wesche, Wade H. Aaron, Richard J. Austin, Patrick A. Baeuerle, (unknown), Bryan D. Lemon, Kenneth G. Sexton, Timothy Z. Yu	5
10	Preclinical and Nonclinical Characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) Targeting B Cell Maturation Antigen (BCMA) for the Treatment of Multiple Myeloma 2018 ·Blood ·Che‐Leung Law, Wade H. Aaron, (unknown), (unknown), (unknown), (unknown), (unknown), Golzar Hemmati, (unknown), (unknown), (unknown), Bryan D. Lemon, (unknown), (unknown), Kenneth G. Sexton, Holger Wesche, Yinghua Xiao, Stephen Yu, (unknown)	12
11	Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jacob A. Kaizerman, Wade H. Aaron, Songzhu An, Richard J. Austin, Matthew A. Brown, (unknown), Tom Huang, Randall W. Hungate, (unknown), Michael G. Johnson, Gary Lee, Brian S. Lucas, Jessica Orf, Minqing Rong, Maria M. Toteva, Dineli Wickramasinghe, Guifen Xu, Qiuping Ye, Wendy Zhong, Dustin L. McMinn	20
12	Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers 2005 ·Biochemical Journal ·Sylvia Herter, Derek E. Piper, Wade H. Aaron, (unknown), Gene Cutler, Ping Cao, Ami S. Bhatt, Youngchool Choe, Charles S. Craik, Nigel P.C. Walker, David Meininger, Timothy Hoey, Richard J. Austin	152
13	Regulation of ACTH levels in anterior pituitary cells during stimulated secretion: evidence for aspartyl and cysteine proteases in the cellular metabolism of ACTH 2003 ·Peptides ·Catherine A. Sei, Thomas Toneff, Wade H. Aaron, Vivian Hook	7
14	Obliteration of α‐melanocyte‐stimulating hormone derived from POMC in pituitary and brains of PC2‐deficient mice 2003 ·Journal of Neurochemistry ·(unknown), Wade H. Aaron, Thomas Toneff, Daesety Vishnuvardhan, Margery C. Beinfeld, Vivian Hook	49
15	β‐Amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for β‐secretase activity in chromaffin vesicles 2002 ·Journal of Neurochemistry ·Vivian Hook, Thomas Toneff, Wade H. Aaron, Sukkid Yasothornsrikul, Richard A. Bundey, Terry Reisine	51
16	Regulation of cellular α-MSH and β-endorphin during stimulated secretion from intermediate pituitary cells: involvement of aspartyl and cysteine proteases in the control of cellular levels of α-MSH and β-endorphin 2002 ·Peptides ·Catherine A. Sei, Thomas Toneff, Wade H. Aaron, Vivian Hook	7
17	Evidence for the Proenkephalin Processing Enzyme Prohormone Thiol Protease (PTP) as a Multicatalytic Cysteine Protease Complex: Activation by Glutathione Localized to Secretory Vesicles 1999 ·Biochemistry ·Sukkid Yasothornsrikul, Wade H. Aaron, Thomas Toneff, Vivian Hook	37
18	[Slightly myelodepressive drugs in the treatment of acute lymphoblastic leukemia in the adult]. 1978 ·PubMed ·(unknown), Wade H. Aaron, (unknown), (unknown), Giovanni Conte, J Pizzuto	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact